V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210034896 | 210010995 | 1.75 | 84.8 | null | 2015-06-14 | 2015-06-14 | IDELALISIB + RITUXIMAB | null | null | 210028034 | IDELALISIB + RITUXIMAB |
| 210034897 | 210011010 | 0 | 76.6 | Disease modification (D) | null | 2016-12-18 | METHOTREXATE | 2 | N | 210028083 | METHOTREXATE |
| 210034898 | 210011023 | 1.7 | 74.5 | Curative (C) | 2018-09-11 | 2018-09-11 | Imatinib 400mg | N | N | 210028127 | IMATINIB |
| 210034899 | 210021151 | null | null | Curative (C) | 2018-01-28 | 2019-01-19 | R Chlorambucil | 02 | N | 210028183 | CHLORAMBUCIL + RITUXIMAB |
| 210034900 | 210011093 | null | null | null | 2015-12-29 | 2015-12-29 | IMATINIB | 99 | null | 210028382 | IMATINIB |
| 210034901 | 210011105 | 1.8 | 87.3 | Curative (C) | 2018-01-26 | 2018-01-26 | ALL UKALL60+ TRIAL | N | N | 210028430 | UKALL60+ |
| 210034902 | 210011107 | null | 84 | Curative (C) | 2018-05-12 | 2018-10-21 | METHOTREXATE | 2 | N | 210028437 | METHOTREXATE |
| 210034903 | 210021190 | 1.65 | null | Curative (C) | 2016-01-11 | 2016-03-05 | ALL UKALL2003 TRIAL | Y | N | 210028497 | UKALL 2003 |
| 210034904 | 210011171 | 1.59 | 67 | Disease modification (D) | 2016-08-03 | 2016-11-20 | Triple / Double Intrathecal Therapy | 2 | N | 210028647 | TRIPLE INTRATHECAL |
| 210034905 | 210011225 | 1.65 | 0 | Adjuvant (A) | 2013-06-05 | 2013-08-05 | Imatinib 400mg | N | N | 210028830 | IMATINIB |
| 210034906 | 210011248 | 1.71 | 69.4 | Curative (C) | 2018-01-17 | 2018-01-23 | METHOTREXATE | N | N | 210028900 | METHOTREXATE |
| 210034907 | 210021255 | 1.66 | 69.3 | Curative (C) | 2017-12-23 | 2018-03-24 | ALL UKALL2003 TRIAL | N | N | 210028901 | UKALL 2003 |
| 210034908 | 210011261 | 1.52 | 77.7 | Disease modification (D) | 2015-02-02 | 2015-07-08 | METHOTREXATE | 02 | N | 210028914 | METHOTREXATE |
| 210034909 | 210011296 | null | 93.25 | Palliative (P) | 2015-06-12 | 2015-09-04 | ALL UKALL60+ TRIAL | N | N | 210029077 | UKALL60+ |
| 210034910 | 210011301 | 0 | 89 | null | 2016-07-16 | 2016-07-23 | IMATINIB | 2 | N | 210029102 | IMATINIB |
| 210034911 | 210011315 | 1.63 | 84 | Curative (C) | 2015-06-25 | 2016-01-03 | Imatinib 400mg | 02 | N | 210029159 | IMATINIB |
| 210034912 | 210011320 | null | 88.4 | Disease modification (D) | 2014-06-21 | 2015-11-19 | R Chlorambucil | 02 | null | 210029163 | CHLORAMBUCIL + RITUXIMAB |
| 210034913 | 210011326 | null | null | Curative (C) | 2016-11-19 | 2016-11-19 | ALL UKALL2003 TRIAL | null | null | 210029191 | UKALL 2003 |
| 210034914 | 210011332 | 1.59 | 80 | Disease modification (D) | 2019-04-01 | 2019-04-01 | IMATINIB | N | N | 210029196 | IMATINIB |
| 210034915 | 210011360 | 1.87 | null | Adjuvant (A) | 2018-06-01 | 2018-08-31 | ALL UKALL2003 TRIAL | N | N | 210029276 | UKALL 2003 |
| 210034916 | 210011364 | 1.8 | 100.9 | Curative (C) | 2016-08-06 | 2016-08-11 | Triple / Double Intrathecal Therapy | 02 | N | 210029291 | TRIPLE INTRATHECAL |
| 210034917 | 210011411 | 1.79 | 88.2 | Palliative (P) | 2013-10-28 | 2014-04-20 | CHLORAMBUCIL + OBINUTUZUMAB | N | N | 210029448 | CHLORAMBUCIL + OBINUTUZUMAB |
| 210034918 | 210011424 | 0 | 94.5 | Disease modification (D) | 2019-05-10 | 2019-08-09 | IDELALISIB + RITUXIMAB | N | N | 210029502 | IDELALISIB + RITUXIMAB |
| 210034919 | 210011488 | 1.6 | 72.5 | Disease modification (D) | 2018-07-25 | 2018-07-25 | Imatinib 600mg | N | N | 210029804 | IMATINIB |
| 210034920 | 210011496 | 0 | 98.4 | Adjuvant (A) | 2018-08-10 | 2018-09-22 | ALL UKALL60+ TRIAL | 1 | N | 210029832 | UKALL60+ |
| 210034921 | 210011508 | 1.86 | 66 | Curative (C) | 2017-03-27 | 2017-04-10 | Triple / Double Intrathecal Therapy | 2 | N | 210029884 | TRIPLE INTRATHECAL |
| 210034922 | 210011538 | 1.6 | 67.8 | Curative (C) | 2018-10-11 | 2018-11-09 | CHLORAMBUCIL + RITUXIMAB | Y | N | 210030000 | CHLORAMBUCIL + RITUXIMAB |
| 210034923 | 210011546 | 1.85 | 95.8 | Curative (C) | 2018-06-24 | 2018-09-16 | IMATINIB | N | N | 210030013 | IMATINIB |
| 210034924 | 210021396 | null | 73.9 | Curative (C) | 2014-09-17 | 2016-04-20 | ALL UKALL60+ TRIAL | null | Y | 210030014 | UKALL60+ |
| 210034925 | 210011569 | null | 73.9 | Curative (C) | 2016-08-13 | 2016-12-27 | Triple Intrathecal | Y | null | 210030141 | TRIPLE INTRATHECAL |
| 210034926 | 210011579 | null | null | Curative (C) | null | 2017-10-31 | IMATINIB | N | N | 210030161 | IMATINIB |
| 210034927 | 210011581 | 1.58 | 90.15 | Palliative (P) | 2018-12-25 | 2019-04-30 | Imatinib 400mg | N | N | 210030163 | IMATINIB |
| 210034929 | 210011638 | 1.76 | 82 | Adjuvant (A) | 2016-11-05 | 2017-04-06 | ALL UKALL2003 B: Ph VII Maintenance | Y | N | 210030435 | UKALL 2003 |
| 210034930 | 210011674 | 1.62 | 64.3 | Palliative (P) | 2016-01-05 | 2016-01-20 | Triple Intrathecal | 2 | N | 210030624 | TRIPLE INTRATHECAL |
| 210034931 | 210011725 | 1.86 | 94.5 | Curative (C) | 2017-01-07 | 2017-05-11 | METHOTREXATE | 02 | N | 210031008 | METHOTREXATE |
| 210034932 | 210011732 | 1.86 | 13.8 | Curative (C) | 2015-09-14 | 2016-05-20 | ALL Int Gde A/B DInt PhIV pt1 PAsp | N | N | 210031025 | ALL INTENSIFICATION |
| 210034933 | 210021507 | null | 67.3 | Curative (C) | 2016-02-23 | 2016-04-04 | Mercaptopurine | N | N | 210031164 | MERCAPTOPURINE |
| 210034934 | 210027514 | 1.75 | null | Curative (C) | 2017-06-04 | 2017-12-08 | ALL Int Gde A/B DInt PhIV pt1 PAsp | Y | N | 210031465 | ALL INTENSIFICATION |
| 210034935 | 210011825 | null | 105.9 | Curative (C) | 2017-09-14 | 2018-01-05 | ALL ALLR3 FLAD Phase IV | Y | N | 210031507 | UKALLR3 |
| 210034936 | 210011833 | null | 41.1 | Curative (C) | 2017-07-22 | 2018-04-06 | ALL Int GdeC D Int PhIV recon Pasp | Y | N | 210031516 | ALL INTENSIFICATION |
| 210034937 | 210027525 | 1.57 | 69.3 | Curative (C) | 2014-01-05 | 2014-06-05 | Blinatumomab | Y | N | 210031542 | BLINATUMOMAB |
| 210034938 | 210011845 | 1.82 | 108.5 | Curative (C) | 2016-11-06 | 2016-11-07 | ALL ALLR3: S/IR Ind Wk 1-4 (pegAsp) | 01 | N | 210031570 | UKALLR3 |
| 210034940 | 210011874 | null | 19.2 | Curative (C) | 2016-09-08 | 2018-12-13 | MERCAPTOPURINE + METHOTREXATE | N | N | 210031749 | MERCAPTOPURINE + METHOTREXATE |
| 210034941 | 210011887 | 1.68 | null | Disease modification (D) | 2013-05-20 | 2014-07-28 | CHOP R - 21 days | Y | null | 210031805 | CHOP R |
| 210034942 | 210011889 | 1.64 | 52 | Palliative (P) | 2016-01-08 | 2016-02-19 | Mercaptopurine | N | N | 210031811 | MERCAPTOPURINE |
| 210034943 | 210031198 | null | 97.2 | Palliative (P) | 2016-03-23 | 2016-09-07 | CHOP R - 21 days | N | N | 210031879 | CHOP R |
| 210034944 | 210011921 | null | 74 | null | 2016-05-08 | 2016-11-09 | ALL Int GdeC D Int PhIV recon Pasp | N | N | 210032019 | ALL INTENSIFICATION |
| 210034945 | 210011926 | null | 78 | Curative (C) | 2014-02-07 | 2014-02-07 | Alemtuz+Fludara+Melphalan RIC MUD | N | null | 210032021 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 210034946 | 210027556 | 1.82 | 85.1 | Curative (C) | 2013-03-26 | 2014-08-21 | ALL Int Guide A/B/C Maint Ph V | Y | N | 210032022 | ALL INTERIM GUIDELINES |
| 210034948 | 210012006 | 1.73 | 51.2 | Curative (C) | 2018-02-16 | 2018-02-16 | Venetoclax | N | N | 210032587 | VENETOCLAX |